In a report released on March 8, Joel Beatty from Robert W. Baird maintained a Buy rating on Cardiff Oncology (CRDF – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.73.
According to TipRanks, Beatty is a 4-star analyst with an average return of 5.2% and a 44.63% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, TRACON Pharmaceuticals, and Leap Therapeutics.
Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $10.00, representing a 478.03% upside. In a report released on March 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Cardiff Oncology’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $128 thousand and a GAAP net loss of $8.7 million. In comparison, last year the company earned a revenue of $133 thousand and had a GAAP net loss of $9.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
Read More on CRDF:
- Cardiff Oncology says no deposits held at Silicon Valley Bank
- Cardiff Oncology price target raised to $15 from $14 at H.C. Wainwright
- Cardiff Oncology reports 2022 EPS (89c), consensus (93c)
- Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
- Cardiff Oncology names Fairooz Kabbinavar as Chief Medical Officer
